预约演示
更新于：2026-08-29
Ketoprofen
酮洛芬
更新于：2026-08-29
概要
基本信息
原研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 中国 (1986-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C16H14O3 |
InChIKeyDKYWVDODHFEZIM-UHFFFAOYSA-N |
CAS号22071-15-4 |
关联
185
项与 酮洛芬 相关的临床试验CTRI/2026/07/113795
EFFICACY OF TRANSDERMAL DICLOFENAC PATCH AND KETOPROFEN PATCH AS POSTOPERATIVE ANALGESIA IN PATIENTS AFTER UNDERGOING THERAPEUTIC EXTRACTION A RANDOMIZED PROSPECTIVE SPLIT MOUTH STUDY - NIL
CTR20262558
酮洛芬贴剂人体生物等效性研究
CTR20262320
酮洛芬贴剂人体生物等效性研究
100 项与 酮洛芬 相关的临床结果
登录后查看更多信息
100 项与 酮洛芬 相关的转化医学
登录后查看更多信息
100 项与 酮洛芬 相关的专利（医药）
登录后查看更多信息
9,434
项与 酮洛芬 相关的文献（医药）2026-12-31Artificial Cells Nanomedicine and Biotechnology
Anticancer activity of fluoxetine Janus dendrimer against cancer cells
Article
作者: Ramirez-Apan, Teresa ; Martínez-Klimova, Elena ; Barajas-Mendoza, Israel ; Martínez-García, Marcos ; Hernández-Rioja, Isabel ; Espinosa-Hernández, Alberto
Targeting the inflammation-related molecules with nonsteroidal anti-inflammatory drugs (NSAIDs) represents a promising approach for cancer prevention/therapy. We evaluated the in vitro anticancer effects of sulindac, ketoprofen, celecoxib and the antidepressant fluoxetine, both free and coupled with synthesized dendrons and dendrimers, on the proliferation and apoptosis of human MCF-7 (human mammary adenocarcinoma), SKLU-1 (human lung adenocarcinoma) and as a control the normal monkey kidney (COS-7) cell line. The antiproliferative activity and cytotoxicity of tested NSAIDs on MCF-7 and SKLU-1 cell lines were assessed by the sulforhodamine B (SRB) assay. The tested dendrons with NSAIDs showed activity against the tumour cell lines. Significant inhibition of the growth of cancer cells was observed for the Janus dendrimers with sulindac-celecoxib, which was selective against MCF-7; and Janus dendrimers with fluoxetine were highly cytotoxic. The fluoxetine-dendrimer could be a candidate for the development of new pharmacological strategies for the treatment and prevention of MCF-7 cancer.
2026-12-01BRAZILIAN JOURNAL OF MICROBIOLOGY
Drug repositioning as an antivirulence strategy: Ketoprofen targets quorum sensing and biofilm in Serratia sp.
Article
作者: Frikha, Fakher ; Aifa, Sami ; Mnif, Sami ; Guesmi, Maha
Serratia sp. are opportunistic Gram-negative bacteria capable of forming robust biofilms and expressing a wide range of quorum sensing (QS)-regulated virulence factors, including motility, protease secretion, and prodigiosin production. The rise of multidrug-resistant strains has emphasized the urgent need for alternative therapeutic strategies targeting bacterial virulence rather than viability. In this context, nonsteroidal anti-inflammatory drugs (NSAIDs) such as ketoprofen have emerged as potential quorum-quenching agents. This study explores the antivirulence activity of ketoprofen against Serratia sp. through a combination of in-vitro phenotypic assays and an advanced in-silico framework. In-vitro assays demonstrated that sub-inhibitory concentrations of ketoprofen significantly impair key virulence traits. Ketoprofen exhibited up to 90.68% inhibition of initial bacterial adhesion and disrupted mature biofilms, reducing biomass by up to 79.1%. Furthermore, motility assays revealed profound inhibition of both swimming and swarming behaviors, alongside a 100% suppression of protease activity and a 60.4% reduction in prodigiosin production, without exerting direct bactericidal effects. To elucidate the molecular basis of this competitive antagonism, an integrative computational approach was deployed. Deep learning-driven molecular docking (GNINA) revealed that ketoprofen targets the LuxR-type QS receptor SmaR with exceptional and reproducible affinity (mean Vina affinity of -9.51 kcal/mol), vastly outperforming natural acyl-homoserine lactone (AHL) autoinducers. Kinetic stability was validated through 5 ns vacuum molecular dynamics (MD), followed by 100 ns explicit solvent MD simulations in independent replicates. The trajectories confirmed remarkable positional retention of the ligand (Ligand RMSD ~ 0.08-0.16 nm) within the binding pocket. Rigorous MM/PBSA free energy calculations on the equilibrated trajectories yielded highly favorable binding free energies (ΔG ranging from - 19.90 to -30.11 kcal/mol), driven by massive enthalpic contributions (ΔH up to -34.20 kcal/mol) and a persistent network engaging 10 to 14 key interacting residues. Overall, these findings demonstrate that ketoprofen acts as a highly stable "molecular plug", effectively outcompeting endogenous AHL signals to lock the SmaR receptor in an inactive state. This highlights ketoprofen's immense potential as a repurposed antivirulence agent for combating biofilm-associated and multidrug-resistant Serratia infections.
2026-10-01THERIOGENOLOGY
Anti-inflammatory drugs disrupt granulosa cell homeostasis in vitro and impair bovine oocyte maturation and embryo development
Article
作者: Pietro, Riccaboni ; Giulia, Gaspari ; Fausto, Cremonesi ; Anna, Lange-Consiglio ; Federica, Di Cesare ; Susanna, Draghi ; Giampaolo, Bosi ; Petra, Cagnardi ; Linda, Ucci
Granulosa cells (GCs) play a crucial role in maintaining follicular homeostasis and supporting the acquisition of oocyte developmental competence. Disruption of GC function may therefore impair oocyte maturation and subsequent embryo development. Although anti-inflammatory drugs are widely used in cattle, their potential direct effects on follicular function and reproductive competence remain poorly understood. The aim of this study was to evaluate whether exposure of bovine GCs to non-steroidal anti-inflammatory drugs (NSAIDs) and a steroidal anti-inflammatory drug (SAID) affects GC viability and morphology, and whether these alterations influence oocyte maturation and embryo developmental competence in vitro. Bovine GCs were exposed to Meloxicam, Flunixin, and Ketoprofen (NSAIDs) or Dexamethasone (SAID) at different concentrations and exposure times. Cell viability and morphology following treatment were evaluated by acridine orange and MTT test. Functional consequences were investigated using a GC-oocyte transwell co-culture system to assess oocyte maturation through first polar body extrusion and subsequent embryo development in vitro. Dexamethasone induced the most pronounced alterations in GC morphology and monolayer integrity. All drug treatments significantly reduced (P < 0.05) the percentages of matured oocytes and blastocyst formation on day 7 compared with controls. On day 11 of embryo culture, Flunixin (5 μM, 8 h) and Ketoprofen (10 μM, 48 h) exerted the most severe effects, as no hatched blastocysts were observed. GC alterations were associated with impaired oocyte developmental competence and reduced embryo developmental potential. These findings suggest that exposure to anti-inflammatory drugs disrupts GC function and impairs oocyte developmental competence and embryo development in vitro.
100 项与 酮洛芬 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 肩周炎 | 日本 | 2007-08-06 | |
| 肌腱病 | 日本 | 2007-08-06 | |
| 肿胀 | 日本 | 1989-09-01 | |
| 镇痛 | 日本 | 1986-11-29 | |
| 炎症 | 日本 | 1986-11-29 | |
| 骨关节炎 | 美国 | 1986-01-09 | |
| 疼痛 | 美国 | 1986-01-09 | |
| 类风湿关节炎 | 美国 | 1986-01-09 | |
| 关节炎 | 中国 | 1986-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 脊椎关节病 | 临床3期 | 中国 | 2026-05-14 | |
| 扭伤和拉伤 | 临床3期 | 中国 | 2026-05-14 | |
| 椎间盘疾病 | 临床3期 | 中国 | 2026-04-10 | |
| 腰痛 | 临床3期 | 中国 | 2026-04-10 | |
| 腰肌劳损 | 临床3期 | 中国 | 2026-04-10 | |
| 肌痛 | 临床3期 | 中国 | 2026-04-10 | |
| 肌筋膜疼痛综合征 | 临床3期 | 中国 | 2026-04-10 | |
| 脊柱炎 | 临床3期 | 中国 | 2026-04-10 | |
| 网球肘 | 临床3期 | 中国 | 2026-04-10 | |
| 腱鞘炎 | 临床3期 | 中国 | 2026-04-10 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | 30 | KSL (KSL 40 mg (Test Product)) | 簾鏇蓋鏇顧簾鑰觸鹽壓(齋鬱醖壓廠壓獵鹹鬱構) = 艱壓鏇鑰艱夢餘夢構艱 鏇鬱夢衊鑰構淵廠願夢 (鏇鹽餘壓製積襯鑰膚獵, 1.17) 更多 | - | 2024-04-19 | ||
OKi (OKi® 80 mg (Reference Product)) | 簾鏇蓋鏇顧簾鑰觸鹽壓(齋鬱醖壓廠壓獵鹹鬱構) = 齋選廠範繭積衊衊製積 鏇鬱夢衊鑰構淵廠願夢 (鏇鹽餘壓製積襯鑰膚獵, 1.38) 更多 | ||||||
N/A | 60 | Extract of ginger+Intravenous ketoprofen (Extract of Ginger) | 夢築簾憲糧膚窪積餘鬱(艱選網醖醖製範膚膚鏇) = 襯願衊鹽繭網壓夢網構 選選願衊廠餘獵鑰獵齋 (範衊網糧蓋鑰鏇膚築獵, 0.04) 更多 | - | 2020-04-07 | ||
Cellulose+Intravenous ketoprofen (Cellulose) | 夢築簾憲糧膚窪積餘鬱(艱選網醖醖製範膚膚鏇) = 鹹襯夢選廠製膚願簾憲 選選願衊廠餘獵鑰獵齋 (範衊網糧蓋鑰鏇膚築獵, 0.07) 更多 | ||||||
N/A | 14 | laboratory biomarker analysis+(RS)2-(3-benzoylphenyl)-propionic acid ((RS)2-(3-benzoylphenyl)-Propionic Acid) | 蓋鬱淵範艱糧襯夢壓製 = 憲遞繭鏇鹹繭蓋窪製衊 鹹醖顧醖簾築網鏇糧齋 (膚網獵窪膚鏇選艱積鹹, 簾膚鹹蓋糧齋窪鹽鏇窪 ~ 觸網鏇憲簾鑰壓襯鬱糧) 更多 | - | 2017-05-18 | ||
placebo for study drug (Placebo for Study Drug) | 蓋鬱淵範艱糧襯夢壓製 = 壓餘襯鬱艱網網鹽鏇積 鹹醖顧醖簾築網鏇糧齋 (膚網獵窪膚鏇選艱積鹹, 鹽壓製範遞壓膚糧繭獵 ~ 糧艱製遞繭遞醖壓築窪) 更多 | ||||||
临床2/3期 | 9 | (Medications) | 遞憲襯簾範衊鏇齋鑰鹽(壓醖網夢廠獵齋鹹願觸) = 製衊製醖鹹醖壓積製鬱 遞鑰齋壓網艱選壓廠廠 (夢糧網憲醖築製蓋鑰艱, 1.94) 更多 | - | 2016-07-15 | ||
placebo (Placebo) | 遞憲襯簾範衊鏇齋鑰鹽(壓醖網夢廠獵齋鹹願觸) = 齋選獵製鑰齋遞淵顧壓 遞鑰齋壓網艱選壓廠廠 (夢糧網憲醖築製蓋鑰艱, 2.3) 更多 | ||||||
临床4期 | 340 | (Parecoxib) | 鏇遞製願衊鬱齋遞壓簾(膚觸鏇繭遞鹽構艱襯餘) = 鹹醖鹽蓋襯窪網構繭廠 壓蓋壓簾襯鑰選獵選鏇 (顧選製窪製鹹構壓廠鏇, 3.35) 更多 | - | 2013-01-28 | ||
(Ketoprofen) | 鏇遞製願衊鬱齋遞壓簾(膚觸鏇繭遞鹽構艱襯餘) = 夢獵廠齋構衊衊艱衊選 壓蓋壓簾襯鑰選獵選鏇 (顧選製窪製鹹構壓廠鏇, 3.46) 更多 | ||||||
临床3期 | 866 | Placebo | 鏇範網蓋簾範遞繭鹹廠(廠艱願鏇顧願蓋醖選衊) = The majority of treatment related adverse events (AE) were dermal AE including erythema (8.6% with 100mg, 8.1% with 50mg, 3.6% with 25 mg ketoprofen and 4.5% with placebo). Other dermal AEs reported with a frequency ranging from 1-5% in any of the ketoprofen treatment groups included skin irritation, dry skin, eczema, contact dermatitis, pruritus and rash. Other AEs had an incidence rate below 1%. 壓製醖觸觸蓋窪醖衊願 (憲簾鏇願鏇網範選簾選 ) | 积极 | 2007-06-13 | ||
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用